Early and profound CD4 + T-cell depletion in gut-associated lymphoid tissue (GALT) may drive Human Immunodeficiency Virus (HIV) immunopathogenesis, and GALT immune reconstitution on highly active antiretroviral therapy (HAART) may be suboptimal. Blood and sigmoid colon biopsies were collected from HAART-treated individuals with undetectable blood HIV RNA for у 4 years and from uninfected controls. HIV proviral levels and T-cell phenotype / function were examined in both compartments. CD4 + T-cell reconstitution in the sigmoid, including CD4 + T cells expressing CCR5, exceeded that in blood and did not differ from uninfected controls. Sigmoid HIV proviral load was not correlated with CD4 + reconsitution, but was correlated with the degree of mucosal CD8 + T-cell immune activation. Colonic Gag-specific T-cell responses were common, but were not associated with proviral load or immune activation. In this select study population, long-term HAART was associated with complete CD4 + T-cell reconstitution in sigmoid colon. However, colonic immune activation may drive ongoing HIV replication.
INTRODUCTION
Human Immunodeficiency Virus-1 (HIV) infects almost 40 million people worldwide. 1 Although HIV infection is characterized by progressive immunodeficiency at a systemic level, HIV is usually acquired across a mucosal surface (the genital or gastrointestinal mucosa), and mucosal events are increasingly recognized as critical to HIV pathogenesis. 2 CD4 + T-cell levels in blood serve as reliable prognostic markers for HIV clinical outcome, but recent studies have shown that the most profound and early CD4 + depletion occurs in the gastrointestinal-associated lymphoid tissue (GALT), which houses up to 80 % of CD4 + T cells in the body. 3 -6 In striking contrast to the gradual depletion of CD4 + T cells observed in peripheral blood, almost 90 % of GALT CD4 + T cells are depleted within 2 weeks of HIV infection, 5,7 -9 and it has been hypothesized that these mucosal events may pave the way for progressive immune dysfunction and death. 10 Highly active antiretroviral therapy (HAART) rapidly reduces the level of plasma HIV viremia and is accompanied by a more gradual reconstitution of blood CD4 + T-cell populations and dramatic improvements in life expectancy. 11 Prior studies have suggested that CD4 + T-cell depletion in the gastrointestinal tract may not be reversed to the same degree as in blood. 12, 13 Although such studies generally evaluated the impact of relatively short-term HAART ( < 4 years), 12, 13 recent work demonstrated incomplete reconstitution in the GALT of the small intestine even after prolonged, effective therapy. 14 This suggests either that immunologic reconstitution in the gastrointestinal tract takes longer than in blood or that HAART is simply unable to reconstitute gastrointestinal CD4 + T-cell populations. As depletion of gastrointestinal CD4 + T cells has been associated with reduced expression of genes important for digestive functions, reduced nutrient absorption, and increased mucosal expression of genes associated with inflammation / immune activation, this may have important clinical consequences. 15, 16 HIV infection is associated with increased immune activation in the GALT. 17 Systemic immune activation has been associated with a higher HIV blood viral load and faster disease progression to acquired immune deficiency syndrome. 18 -20 Regulatory T cells (CD4 + CD25 + ) that suppress immune activation have been associated with lower HIV viremia and higher peripheral CD4 / CD8 T-cell ratios. 21, 22 HIV-specific cellular Immune reconstitution in the sigmoid colon after long-term HIV therapy ARTICLES immune responses also play an important role in host immune control. 23, 24 Specifically, CD8 + T-cell immune responses targeting HIV Gag have been associated with lower HIV RNA plasma viral load and delayed disease progression to acquired immune deficiency syndrome. 24, 25 Strong HIV-specific CD8 + T-cell responses may be present in the gastrointestinal mucosa of HIV-infected individuals, 26 although their role in local (mucosal) HIV immune control and / or immunopathogenesis is not clear.
We hypothesized that, due to the absence of local HIV replication, long-term suppressive HAART would be associated with complete immune reconstitution in the sigmoid colon and a loss of HIV-specific CD8 + T-cell responses in both the blood and the colonic mucosa. To address this hypothesis, we have examined the phenotype and function of T cells from the blood and sigmoid colon of HIV-infected men on long-term, completely suppressive HAART.
RESULTS

Study participants
The study population consisted of 23 HIV-infected men on long-term HAART and three HIV-uninfected controls ( Table 1 ). The mean duration of prior HAART was 120 months (range, 51 -216 months), and the mean duration of viral suppression below the level of detection was 89 months (range, 49 -130 months). Therapy had been initiated for a mean of 28 months (range, 2 -108 months) after the first HIV-positive enzymelinked immunosorbent assay. For those participants with data available, the mean nadir CD4 + T-cell count had been 183 / mm 3 (range, 32 -360 / mm 3 ).
CD4 + T-cell populations in the blood and the sigmoid colon
The proportion of T cells expressing CD4 + in the sigmoid colon of highly supressed participants was significantly higher than that in the peripheral blood (mean, 56 vs. 45 % , respectively; paired t -test P = 0.001; Figure 1a and b ) and was similar to that seen in HIV-uninfected controls (mean, 56 vs. 64 % ; P = 0.14; Figure 1a and b ). However, blood CD4 + T-cell proportions in blood remained lower in HIV-infected participants (45 vs. 65 % respectively, P = 0.008; Figure 1a ).
Earlier studies described incomplete reconstitution of CD4 + T cells coexpressing CCR5 + in the recto-sigmoid despite HAART. 13 CCR5 + expression was assayed in 10 out of 23 (43 % ) HIV-infected participants on long-term HAART, with similar Abbreviations: HAART, highly active antiretroviral therapy; HIV, Human Immunodefi ciency Virus; NA, not applicable. a The sensitivity of viral load assays varied over time, from a threshold of >10,000 RNA copies/ml (1995) to >50 RNA copies/ml (currently).
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levels as in HIV-negative controls seen in both blood (mean % CD4 + CCR5 + , 1.8 vs. 3.8 % respectively; P = 0.15; Figure 1c and d) and sigmoid colon (mean % CD4 + CCR5 + , 47 vs. 53 % respectively, P = 0.53; Figure 1c and d ).
Participants had been on HAART for different lengths of time (range, 51 -216 months), and the duration of complete viral suppression also varied (range, 49 -130 months). The prior duration of HAART did not correlate with CD4 + T-cell reconstitution in blood ( r = 0.16; P = 0.50) or sigmoid colon ( r = 0.14; P = 0.55), although those treated for >10 years tended to have higher sigmoid CD4 + T-cell proportions than those treated for < 5 years (58 vs. 50 % , respectively; P = 0.065). Although the duration of undetectable viral load in blood correlated with improved blood CD4 + T-cell reconstitution ( r = 0.62; P = 0.002), this was not the case for sigmoid ( r = 0.18; P = 0.6). Pretherapy nadir CD4 + T-cell counts did not correlate with immune reconstitution at either site (data not shown).
Associations of HIV proviral load in CD4 + T cells in blood and sigmoid colon
HIV RNA was undetectable in blood of all HIV-infected individuals, and was not measured in sigmoid colon. HIV proviral DNA was assayed in the blood of all participants and in the sigmoid colon of 11 out of 23 individuals (48 % ). Although there was a negative correlation between proviral HIV DNA levels and CD4 + T-cell proportions in blood ( r = − 0.41; P = 0.04; Figure 2a ), no such correlation was observed in the sigmoid colon ( r = 0.31; P = 0.39). As CD4 + T-cell populations in blood and sigmoid were isolated using different techniques, we were unable to directly compare proviral HIV DNA levels between these two compartments.
Expression of the early activation marker CD69 was much higher in colonic than in peripheral blood T cells, as expected, on both CD4 + T cells (40.7 vs. 0.3 % ; P < 0.001; Figure 2b ) and CD8 + T cells (35.4 vs. 0.7 % ; P < 0.001; Figure 2b ). The same applied to expression of HLA-DR by colonic CD4 + T cells (3.2 vs. 0.4 % , respectively; P < 0.001). However, levels of CD69 and HLA-DR expression did not differ between HAART-treated and HIV-negative controls on sigmoid CD4 + (CD69, 40.7 vs. 54.7 % ; P = 0.27; HLA-DR, 3.2 vs. 4.4 % ; P = 0.57) or CD8 + T cells (CD69, 35.4 vs. 24.8 % ; P = 0.25). Colonic HIV proviral DNA levels were correlated with increased mucosal CD8 + T-cell immune activation, as reflected by CD69 + expression ( r = 0.7; P = 0.02; Figure 2c ). 
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HIV-specific T-cell responses
HIV Gag-specific T-cell responses were measured in blood and the sigmoid colon of 16 out of 23 (70 % ) participants. Interferonand / or tumor necrosis factor-immune responses against HIV Gag were detected in the colon of seven out of 16 (44 % ) and in the blood of 10 out of 16 (63 % ) patients ( Figure 3a ) . There was no association between CD4 / CD8 + T-cell ratio and the presence or absence of HIV Gag-specific T-cell responses in either compartment (sigmoid, 50 vs. 55 % ; P = 0.46; blood, 45 vs. 48 % ; P = 0.5). Likewise, no association was seen between CD4 / CD8 + T-cell ratio and the strength of HIV-specific T-cell responses, using either interferon-or tumor necrosis factor-as a functional output. Neither CD4 + nor CD8 + T-cell responses in the blood or the sigmoid colon were associated with HIV proviral DNA levels at their respective sites ( P >0.4 for both, Figure 3b ).
Regulatory T-cell populations in blood and the sigmoid colon
Regulatory T cells were defined as CD4 + T cells expressing both FoxP3 and CD25 (representative dot plot; Figure 4a ), and were significantly increased in sigmoid colon relative to blood in HIVinfected participants (mean, 1.2 vs. 0.2 % of CD4 + T cells; paired t -test P = 0.002; Figure 4b ) and HIV-negative controls (data not shown). Regulatory T-cell proportions were much lower in the blood of HIV-infected individuals on long-term HAART than in HIV-uninfected controls (mean, % CD4 + CD25 + FoxP3 + , 0.18 vs. 1.12 % , respectively; P = 0.009), but in contrast to previous reports 27 did not differ in the sigmoid colon (0.56 vs. 0.88 % , respectively; P = 0.49). T-regulatory populations in the sigmoid colon did not correlate with mucosal immune activation, although in blood there was a positive correlation with CD4 + T-cell expression of HLA-DR ( r = 0.57; P = 0.02). There were no association in either compartment between regulatory T-cell populations and duration of therapy or time to initiation of therapy ( P >0.1 for both).
DISCUSSION
The early damage inflicted by HIV at the level of the host gastrointestinal mucosa may set the stage for subsequent systemic inflammation and progressive immune dysfunction. 5, 28, 29 Despite the dramatic effects of HAART on blood CD4 + T-cell counts and host survival, it has been unclear to what degree antiretroviral therapy is able to correct these mucosal immune defects, as significantly reduced CD4 / 8 + T-cell ratios persist despite effective therapy. 13, 30 It is therefore encouraging that, in this selected cohort of HIV-infected men on long-term suppressive HAART, CD4 + T-cell reconstitution in the sigmoid colon actually exceeded that observed in the blood, with CD4 + T-cell proportions in the colonic mucosa of HAART-treated men approximating those of HIV-uninfected controls. Furthermore, similar degrees of reconstitution were observed in the proportion of colonic CD4 + T-cells expressing the HIV coreceptor and ARTICLES activation marker CCR5. However, although increased CD4 + T-cell proportions in the gastrointestinal mucosa have been linked to increased expression of genes involved in growth / repair and reduction in the expression of genes associated with inflammation, cell activation, and ultimately slower disease progression, 30 the clinical implications of our findings are not known.
The highly selected participants in this study had unusually complete virus suppression on HAART, but results from this subgroup clearly demonstrate that normalization of colonic CD4 + T-cell proportions is possible on HAART. Prior studies have found persistent depletion of CD4 + T cells in the rectosigmoid colon, particularly CD4 + cells expressing CCR5, after 3 years or more of HAART. 13 Our positive findings might relate to the increased duration and perhaps more complete viral suppression in our study population. However, a very recent study found that GALT immune reconstitution was incomplete in the terminal ileum (lower small intestine) of a similar highly suppressed patient population. 14 Although small intestinal biopsies were not collected in our study, this suggests the possibility that there may be differential immune reconstitution in the mucosa of the large vs. small intestine after long-term viral suppression on HAART. Confirmation of this hypothesis will require further studies with sampling of both the large and the small intestinal mucosa.
HIV preferentially infects and replicates in activated CD4 + T cells. This may underlie the viral predilection for the gastrointestinal mucosa, where the number of activated, proliferating CD4 + T cells is high. 13 Levels of immune activation may be elevated in both blood and colonic mucosa of HIV-infected, therapy-naive individuals, based on expression of HLA-DR. 13 Immune activation in the colon of our participants on long-term HAART, as assayed by expression of HLA-DR and the activation marker CD69, was similar to uninfected controls. Despite this, the size of HIV proviral reservoir in the colon was correlated with the degree of CD8 + T-cell immune activation, implying that even a " normalized " level of immune activation in the gut mucosa may be sufficient to support low-level virus replication despite HAART.
In HAART-naive individuals, HIV Gag-specific CD8 + T-cell responses in blood have been associated with reduced viremia and slower disease progression. 24 HIV-specific CD8 + T-cell responses are also detectable at mucosal sites, including the gut, 31 cervix, 32, 33 and semen, 34, 35 although their clinical significance at these mucosal sites is less clear. In our highly suppressed participants, Gag-specific CD8 + (and to a lesser degree CD4 + ) T-cell immune responses were often detectable in the blood and the colonic mucosa, but neither their presence nor their magnitude was associated with the degree of CD4 + T-cell reconstitution 
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or the HIV latent proviral DNA load at either site. However, we examined only a limited repertoire of T-cell immune functions (production of tumor necrosis factor-and interferon-), and the immune techniques used did not permit us to determine the clonal diversity of the HIV-specific T-cell immune responses observed. Specifically, responses may have represented the preservation or reconstitution of a clonally diverse T-cell population, or the re-expansion of an oligo-clonal response from a small reservoir of memory effector T cells. In addition, cell numbers did not permit detailed mapping of the antigen specificity of the responses seen, a factor that may impact host immune control of virus. Nonetheless, as blood HIV-specific CD8 + responses wane on HAART, in the absence of antigenic stimulation, 36 the detection of responses in our participants implies that there is ongoing low-level viral replication in blood and sigmoid colon despite long-term suppressive therapy.
In summary, levels of CD4 + T-cell reconstitution in the sigmoid colon of this selected group on highly suppressive antiretroviral therapy actually exceeded those observed in blood, with CD4 / CD8 + ratios comparable to uninfected controls. However, the persistence of HIV-specific CD8 + T-cell responses in both the blood and the recto-sigmoid suggests that there may be ongoing low-level HIV replication in the gastrointestinal mucosa despite prolonged undetectable viremia. Although complete normalization of CD4 + T-cell proportions in the sigmoid colon can be achieved on long-term suppressive HAART, the clinical importance of such normalization remains unclear and will be an important area for further study.
METHODS
Study participants . HIV-infected and -uninfected controls were recruited through the Canadian Immunodeficiency Research Collaborative at the Maple Leaf Medical Clinic in Toronto, Canada. All HIV-infected participants had been on uninterrupted HAART for at least 48 months with an undetectable blood HIV viral load ( < 50 copies / ml). All subjects provided informed, written consent. The study protocol was approved by Research Ethics Boards at the University Health Network, Toronto, the University of Toronto, and St Michael ' s Hospital, Toronto.
Sampling protocol . Blood was obtained by venipuncture and collected into Acid Citrate Dextran solution A (BD Bioscience, La Jolla, CA). Plasma viremia was determined using the Versant HIV-1 RNA 3.0 assay (bDNA; Bayer Diagnostics, Puteaux Cedex, France). Peripheral blood mononuclear cells were isolated by density centrifugation as previously described. 34 Between 20 and 25 biopsies were obtained from the recto-sigmoid, approximately 25 -30 cm from the anal verge. Biopsies were immediately placed into RPMI containing 100 U ml − 1 penicillin, 100 g ml − 1 streptomycin, and 1 × GlutaMAX-1 (Invitrogen, Carlsbad, CA). Colonic mucosal mononuclear cells were isolated by digestion with 0.5 -1.0 mg ml − 1 of Collagenase type II (Clostridiopeptidase A; SigmaAldrich, St Louis, MI) for 30 min on a stirring heating block. The digested cell suspension was filtered through a 100-m filter and enumerated.
Evaluating HIV-specific immune responses ex vivo . HIV Gagspecific CD4 + and CD8 + T cell-specific immune responses were measured in blood and the sigmoid colon, using modifications of a previously described protocol. 34 One million colonic mucosal mononuclear cells and peripheral blood mononuclear cells were incubated in media with 2 % dimethyl sulfoxide (negative control), or stimulated using Staphlococcus enterotoxin-B (SEB, positive control; 3 g ml − 1 ) or Gag Clade-B peptide pool (1 g ml − 1 per peptide) for 1 h at 37 ° C and 5 % CO 2 . No costimulatory molecules were used. Clade-B Gag pool was made up of 122 15-mer overlapping peptides encompassing the entire Gag gene. Brefeldin A (1 g ml − 1 ) was added, and samples were incubated for another 5 h at 37 ° C and 5 % CO 2 . Samples were washed with 1 % fetal bovine serum -phosphate-buffered saline, permeabilized, and stained with fluorochrome-labeled monoclonal antibodies specific for CD8, CD3, tumor necrosis factor-, and interferon-(Becton Dickinson Immunocytometry Systems, San Jose, CA). Samples were acquired using a FACSCalibur flow cytometer (BD Systems) and data analysis performed using Flow Jo analytical software version 7.2.2 (Treestar, Ashland, OR). A positive response was defined as background-corrected cytokine production in the HIV Gag well exceeding 0.05 % of gated cells and background levels of cytokine production by at least twofold.
Measurement of proviral HIV DNA . CD4 + T cells were isolated from peripheral blood mononuclear cells using a column-based cell separation technique (StemCell Technologies, Vancouver, BC, Canada) as previously described. 37 To determine the proviral HIV DNA copies per million CD4 + T cells, genomic DNA was isolated using the Puregene DNA isolation kit according to the manufacturer ' s specifications (Gentra, Minneapolis, MN). One microgram of DNA was then used as template for real-time PCR in an iCycler (Bio-Rad, Hercules, CA). The amplification reaction was carried out in triplicate using 0.5 M primers, 0. 
